$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415066028 Filed on November 16, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$570.0K	$1.070M	$1.030M
YoY Change	-44.66%	24.42%	87.27%
% of Gross Profit
Research & Development	$830.0K	$1.500M	$1.640M
YoY Change	-49.39%	-4.58%	92.94%
% of Gross Profit
Depreciation & Amortization	$20.00K	$20.00K	$30.00K
YoY Change	-33.33%	-33.33%	50.0%
% of Gross Profit
Operating Expenses	$1.400M	$2.570M	$2.670M
YoY Change	-47.57%	5.85%	90.71%
Operating Profit		-$2.571M
YoY Change		5.8%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$10.00K	-$30.00K	-$60.00K
YoY Change	-116.67%	-400.0%	-135.29%
Pretax Income	-$1.380M	-$2.600M	-$2.730M
YoY Change	-49.45%	7.44%	120.16%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.380M	-$2.603M	-$2.730M
YoY Change	-49.45%	7.52%	123.77%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$74.35K	-$140.7K	-$178.7K
COMMON SHARES
Basic Shares Outstanding	18.50M shares		15.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.96M	$17.15M	$8.540M
YoY Change	86.89%	62.25%	144.0%
Cash & Equivalents	$428.0K	$710.0K	$4.251M
Short-Term Investments	$15.53M	$16.44M	$4.290M
Other Short-Term Assets	$70.00K	$120.0K	$30.00K
YoY Change	133.33%	33.33%	0.0%
Inventory
Prepaid Expenses		$117.0K	$52.00K
Receivables	$760.0K	$820.0K	$1.010M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.79M	$18.09M	$9.598M
YoY Change	74.91%	62.88%	115.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$271.0K	$268.0K	$313.0K
YoY Change	-13.42%	-0.74%	21.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$292.0K		$333.0K
YoY Change	-12.31%		1565.0%
Total Long-Term Assets	$292.0K	$268.0K	$313.0K
YoY Change	-6.71%	-8.53%	11.79%
TOTAL ASSETS
Total Short-Term Assets	$16.79M	$18.09M	$9.598M
Total Long-Term Assets	$292.0K	$268.0K	$313.0K
Total Assets	$17.08M	$18.36M	$9.911M
YoY Change	72.33%	61.04%	109.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.169M	$335.0K	$1.542M
YoY Change	-24.19%	-74.23%	576.32%
Accrued Expenses	$1.500M	$2.308M	$1.347M
YoY Change	11.36%	181.46%	53.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.952M	$2.838M	$3.113M
YoY Change	-5.17%	18.25%	133.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$120.0K
YoY Change	-100.0%	-100.0%	-81.82%
Total Long-Term Liabilities	$0.00	$0.00	$123.0K
YoY Change	-100.0%	-100.0%	-81.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.952M	$2.838M	$3.113M
Total Long-Term Liabilities	$0.00	$0.00	$123.0K
Total Liabilities	$2.952M	$2.838M	$3.236M
YoY Change	-8.78%	13.57%	62.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.14M	-$68.76M	-$61.65M
YoY Change	13.77%	16.69%	17.64%
Common Stock	$84.27M	$84.28M	$68.33M
YoY Change	23.33%	24.26%	23.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.13M	$15.52M	$6.675M
YoY Change
Total Liabilities & Shareholders Equity	$17.08M	$18.36M	$9.911M
YoY Change	72.33%	61.04%	109.71%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$1.380M	-$2.603M	-$2.730M
YoY Change	-49.45%	7.52%	123.77%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$30.00K
YoY Change	-33.33%	-33.33%	50.0%
Cash From Operating Activities	-$1.290M	-$2.530M	-$2.010M
YoY Change	-35.82%	126.09%	25.63%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$12.00K	-$70.00K
YoY Change	-71.43%		600.0%
Acquisitions
YoY Change
Other Investing Activities	$910.0K	$1.950M	-$2.690M
YoY Change	-133.83%	-221.12%	-156.16%
Cash From Investing Activities	$900.0K	$1.940M	-$2.760M
YoY Change	-132.61%	-220.8%	-157.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	110.0K	0.000	50.00K
YoY Change	120.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.290M	-2.530M	-2.010M
Cash From Investing Activities	900.0K	1.940M	-2.760M
Cash From Financing Activities	110.0K	0.000	50.00K
Net Change In Cash	-280.0K	-590.0K	-4.720M
YoY Change	-94.07%	-74.99%	-247.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.290M	-$2.530M	-$2.010M
Capital Expenditures	-$20.00K	$12.00K	-$70.00K
Free Cash Flow	-$1.270M	-$2.542M	-$1.940M
YoY Change	-34.54%	127.17%	22.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1347000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	268000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313000	USD
CY2015Q3	us-gaap	Assets Assets	18359000	USD
CY2014Q4	us-gaap	Assets Assets	9911000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	335000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1542000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2308000	USD
CY2015Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	195000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2838000	USD
CY2015Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	123000	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	123000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	2838000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	3236000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	84265000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68317000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68757000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61653000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	15521000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	6675000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18359000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9911000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18498289	shares
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	4290000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	9598000	USD
CY2014Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	1005000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	18091000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
CY2015Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	823000	USD
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	BCLI
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	16441000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3129000	USD
CY2015Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	117000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	52000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1626000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-35000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-2421000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.14
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4755000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	224000	USD
	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4123000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6117000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	12151000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12181000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14757000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	198000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3113000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2480000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	1761000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7104000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6516000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.39
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.50
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18354580	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13122133	shares
CY2015Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	32000	USD
CY2014Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-9000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2603000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.16
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18480957	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15158411	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7139000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2571000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2430000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1024000	USD
CY2014	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9554000	USD
CY2014	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
CY2014	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
CY2014	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	701000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	108000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	955000	USD
	bcli	Exercise Of Equity Classified Warrants ExerciseOfEquityClassifiedWarrants	2333000	USD
	bcli	Exercise And Reissuance Of Warrants Value ExerciseAndReissuanceOfWarrantsValue	12409000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	73000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	80000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1724000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	932000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-13000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1207000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1076000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	955000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	578000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	108000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	186000	USD
CY2015Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	26000	USD
CY2014Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	30000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-38000	USD
CY2015Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	732000	USD
CY2014Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	66000	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-420000	USD
CY2014Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	547000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2530000	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1119000	USD
CY2015Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	287000	USD
CY2014Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	280000	USD
CY2015Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	1600000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-1000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1693000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9639000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3541000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5466000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8969000	USD
CY2015Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	USD
CY2014Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2015Q3	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-1953000	USD
CY2014Q3	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	1600000	USD
CY2015Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	2000	USD
CY2014Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	6000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1939000	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1606000	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
CY2014Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	366000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-591000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2359000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1301000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11328000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9554000	USD
CY2015Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12409000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2015Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	600000	USD
CY2015Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-104000	USD
CY2014Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	2348000	USD
	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	685000	USD
CY2015Q3	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	0	USD
CY2014Q3	bcli	Proceeds From Issuance Of Equity ProceedsFromIssuanceOfEquity	470000	USD
CY2009Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	74667	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	955000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	764000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	287000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	355000	USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18480957	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18480957	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15281497	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15281497	shares
	bcli	Exercise Of Liability Classified Warrants ExerciseOfLiabilityClassifiedWarrants	145000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	-42000	USD
CY2015Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	130000	USD
	bcli	Noncash Financing Activities NoncashFinancingActivities	1675000	USD
CY2015Q3	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
CY2014Q3	bcli	Noncash Financing Activities NoncashFinancingActivities	0	USD
	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-119000	USD
	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-405000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 56.7pt" align="justify"></div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 66pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="88"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">c.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of estimates</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 66pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0in 0.79in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	bcli	Interest Bearing Bank Deposits Maturity Date InterestBearingBankDepositsMaturityDate	P6M
CY2014	bcli	Interest Bearing Bank Deposits Maturity Date InterestBearingBankDepositsMaturityDate	P5M
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1633000	USD
CY2015Q3	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014Q3	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	-130000	USD
CY2015Q3	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	552000	USD
CY2014Q3	bcli	Increase Decrease In Accounts Receivable And Prepaid Expenses IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses	-341000	USD
	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure

Files In Submission

Name	View Source	Status
0001144204-15-066028-index-headers.html	Edgar Link	pending
0001144204-15-066028-index.html	Edgar Link	pending
0001144204-15-066028.txt	Edgar Link	pending
0001144204-15-066028-xbrl.zip	Edgar Link	pending
bcli-20150930.xml	Edgar Link	completed
bcli-20150930.xsd	Edgar Link	pending
bcli-20150930_cal.xml	Edgar Link	unprocessable
bcli-20150930_def.xml	Edgar Link	unprocessable
bcli-20150930_lab.xml	Edgar Link	unprocessable
bcli-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423105_10q.htm	Edgar Link	pending
v423105_ex10-4.htm	Edgar Link	pending
v423105_ex10-5.htm	Edgar Link	pending
v423105_ex31-1.htm	Edgar Link	pending
v423105_ex31-2.htm	Edgar Link	pending
v423105_ex32-1.htm	Edgar Link	pending
v423105_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q4 Form 10-Q Financial Statement

#000114420415066028 Filed on November 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2015 Q4 Form 10-Q Financial Statement

#000114420415066028 Filed on November 16, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli